XNCR

+ Watchlist + Portfolio

Xencor, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $27.52
52-Week Range: $7.13 – $27.70
Market Cap: $2.01B
P/E (TTM): —
EPS (TTM): -2.16
Dividend Yield: —

Advanced Metrics

Price/Book: 3.05
PEG Ratio: —
Return on Equity: -29.07%
Return on Assets: -16.84%
Gross Margin: -143.65%
Operating Margin: -72.37%
Profit Margin: -155.59%
Current Ratio: 6.39
Debt/Equity: 0.34
Total Debt: $170.11M
Free Cash Flow: $-94.54M
Revenue Growth: 17.50%
Earnings Growth: —
Enterprise Value: $1.72B

XNCR Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$164.58M	$174.62M	$110.49M	$125.58M
Research & Development	$199.56M	$253.60M	$227.69M	$239.43M
Selling, General & Admin	$47.49M	$53.38M	$61.22M	$63.64M
Operating Expenses	$247.05M	$306.98M	$288.90M	$303.08M
Operating Income	-$82.47M	-$132.36M	-$178.41M	-$177.50M
EBITDA	-$45.70M	-$101.96M	-$186.17M	-$47.19M
Pretax Income	-$54.51M	-$119.63M	-$234.92M	-$89.63M
Income Tax	$673.00K	$13.66M	$1.62M	$2.50M
Net Income	-$55.18M	-$133.13M	-$232.62M	-$91.92M
Diluted EPS	-0.93	-2.08	-3.58	-1.24
Diluted Shares	59.65M	60.50M	65.04M	74.24M

XNCR Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$53.94M	$53.79M	$40.88M	$54.07M
Receivables	$29.00M	$23.74M	$60.85M	$29.30M
Current Assets	$675.34M	$635.60M	$577.60M	$599.82M
Total Assets	$846.27M	$965.13M	$951.95M	$875.50M
Current Liabilities	$63.84M	$73.92M	$87.43M	$95.91M
Long-Term Debt	—	$161.77M	$115.16M	$76.48M
Total Debt	$59.63M	$251.94M	$231.95M	$187.75M
Total Liabilities	$118.77M	$303.05M	$277.92M	$239.91M
Retained Earnings	-$338.29M	-$471.42M	-$704.04M	-$795.96M
Shareholders' Equity	$727.50M	$661.75M	$677.61M	$635.59M
Working Capital	$611.50M	$561.69M	$490.17M	$503.91M
Net Debt	—	$135.69M	$122.73M	$65.68M

XNCR Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$24.48M	-$77.93M	-$202.19M	-$135.12M
Capital Expenditure	-$43.40M	-$21.25M	-$9.51M	-$3.15M
Free Cash Flow	-$18.92M	-$99.18M	-$211.70M	-$138.27M
Depreciation & Amortisation	$8.80M	$11.50M	$12.11M	$10.51M
Stock-Based Compensation	$48.91M	$53.76M	$53.28M	$43.23M
Investing Cash Flow	-$119.72M	-$111.06M	-$7.87M	$139.99M
Financing Cash Flow	$5.70M	$189.22M	$197.15M	$8.23M
Net Change in Cash	-$89.54M	$228.00K	-$12.91M	$13.10M

XNCR Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$32.73M	$43.61M	$21.00M	$28.24M	$4.52M
Research & Development	$58.58M	$61.66M	$54.37M	$64.82M	$64.67M
Selling, General & Admin	$17.34M	$15.12M	$14.15M	$17.04M	$17.71M
Operating Expenses	$75.92M	$76.78M	$68.52M	$81.86M	$82.38M
Operating Income	-$43.18M	-$33.17M	-$47.52M	-$53.63M	-$77.86M
EBITDA	-$36.91M	-$20.18M	$4.23M	$5.67M	-$121.37M
Pretax Income	-$48.27M	-$31.07M	-$6.03M	-$4.27M	-$128.64M
Income Tax	$367.00K	-$250.00K	$0.00	$2.39M	$280.00K
Net Income	-$48.42M	-$30.82M	-$6.03M	-$6.65M	-$128.92M
Diluted EPS	-0.66	-0.41	-0.08	-0.09	-1.71
Diluted Shares	73.67M	74.28M	74.41M	74.59M	75.25M

XNCR Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$39.67M	$44.44M	$28.29M	$54.07M	$14.17M
Receivables	$37.78M	$47.55M	$21.80M	$29.30M	$12.00M
Current Assets	$521.27M	$513.15M	$518.44M	$599.82M	$482.86M
Total Assets	$904.69M	$879.42M	$868.81M	$875.50M	$736.85M
Current Liabilities	$88.44M	$96.08M	$86.48M	$95.91M	$73.46M
Long-Term Debt	—	—	—	$76.48M	$82.12M
Total Debt	$67.82M	$67.93M	$69.27M	$187.75M	$175.16M
Total Liabilities	$264.81M	$259.07M	$243.50M	$239.91M	$221.21M
Retained Earnings	-$752.45M	-$783.28M	-$789.31M	-$795.96M	-$924.88M
Shareholders' Equity	$639.87M	$620.35M	$625.32M	$635.59M	$515.63M
Working Capital	$432.83M	$417.07M	$431.96M	$503.91M	$409.40M
Net Debt	—	—	—	$65.68M	$94.36M

XNCR Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$16.22M	-$36.37M	-$30.82M	-$51.71M	-$67.63M
Capital Expenditure	-$1.44M	-$383.00K	-$183.00K	-$1.14M	-$610.00K
Free Cash Flow	-$17.66M	-$36.75M	-$31.00M	-$52.85M	-$68.24M
Depreciation & Amortisation	$2.69M	$2.65M	$2.59M	$2.58M	$2.57M
Stock-Based Compensation	$12.21M	$10.74M	$10.09M	$10.19M	$9.56M
Investing Cash Flow	$13.67M	$40.48M	$14.67M	$71.17M	$26.68M
Financing Cash Flow	$1.25M	$662.00K	$0.00	$6.32M	$950.00K
Net Change in Cash	-$1.30M	$4.77M	-$16.15M	$25.78M	-$40.00M

Market Snapshot

About

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. The company uses its proprietary XmAb protein engineering technology platform to create next-generation antibody therapeutics with improved efficacy and safety profiles. Xencor has multiple product candidates in clinical development and partners with leading pharmaceutical companies.